[Skip to Content]
[Skip to Content Landing]
August 1969

Children Immunized With HPV-77 Rubella VaccineAdditional Laboratory Observations

Author Affiliations

From the Research Division of Infectious Diseases, Children's Hospital Medical Center (Drs. Katz and Wilfert); the Children's Medical Service, Massachusetts General Hospital (Drs. Lang, Feigin, and Goldfein); and the Department of Pediatrics, Harvard Medical School, Boston. Drs. Katz, Lang, and Wilfert are now at Duke University School of Medicine, Durham, NC. Dr. Feigin is now at Washington University School of Medicine, St. Louis.

Am J Dis Child. 1969;118(2):213-217. doi:10.1001/archpedi.1969.02100040215010

FROM THE first reports1,2 of data obtained in careful clinical investigations of susceptible children to whom live HPV-77 African green monkey kidney (GMK) rubella vaccine was administered, several characteristics of the attenuated infection became apparent. As other investigators confirmed and extended, these initial results over a three-year period, the original features have been strikingly consistent.3-5 They include the successful establishment of an infection which is usually occult, the intermittent shedding of vaccine virus from the pharynx during the period from one to three weeks after immunization, the absence of communicability to susceptible contacts, a failure to develop detectable viremia, and the appearance in two to four weeks postinoculation of type-specific serum antibody with both hemagglutination-inhibiting (HI) and virus-neutralizing (VN) activities but no measurable complement-fixing antibody. In collaborating with Drs. Parkman and Meyer to enlarge the experience with this experimental vaccine, our continuing interest in the patterns of interaction

First Page Preview View Large
First page PDF preview
First page PDF preview